Izana Bioscience

About:

Izana Bioscience is a biopharmaceutical company focused on bringing innovative science to market.

Description:

Izana Bioscience is a biopharmaceutical company focused on bringing innovative science to market. Izana Bioscience are developing a monoclonal antibody therapy, namilumab (IZN-101), targeting granulocyte macrophagecolony stimulating factor (GM-CSF). IZN-101 is under investigation for its use against the ongoing COVID-19 pandemic, to halt the rapid deterioration of patients with acute respiratory distress.

Total Funding Amount:

1.35M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Oxford, Oxfordshire, United Kingdom

Founded Date:

2017-01-01

Founders:

Someit Sidhu

Number of Employees:

1-10

Last Funding Date:

2017-12-14

IPO Status:

Private

Industries: